| 1 |
28587581 | ACE Phenotyping as a Guide Toward Personalized Therapy With ACE Inhibitors. | 2017 Jul |
1 |
| 2 |
27924184 | Revealed Opportunism: How Physicians "Game" Prior Authorization Protocols Until They Are Rescinded. | 2016 Sep |
1 |
| 3 |
28905031 | Update of treatment of heart failure with reduction of left ventricular ejection fraction. | 2016 |
1 |
| 4 |
20086184 | Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. | 2010 Feb |
1 |
| 5 |
19436650 | Candesartan cilexetil in the treatment of chronic heart failure. | 2009 |
2 |
| 6 |
18366776 | Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients. | 2008 Mar 26 |
1 |
| 7 |
18594050 | Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan. | 2008 Jul |
3 |
| 8 |
17395047 | Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. | 2007 Mar |
1 |
| 9 |
17824291 | Effects of different AT1-receptor antagonists in the therapy of severe heart failure pretreated with ACE inhibitors. | 2007 Aug |
1 |
| 10 |
16601570 | Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. | 2006 Mar |
2 |
| 11 |
16644319 | Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. | 2006 May |
4 |
| 12 |
17061457 | [Angiotensin receptor blockers and cardiac rhythm disorders]. | 2006 Jul-Aug |
1 |
| 13 |
17245479 | Improving outcomes in chronic heart failure. | 2006 Dec |
2 |
| 14 |
17699280 | Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors. | 2006 Jul |
3 |
| 15 |
15857354 | A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure. | 2005 May |
2 |
| 16 |
16028461 | Clinical update: the role of angiotensin II receptor blockers in patients with left ventricular dysfunction (Part II of II). | 2005 Jun |
1 |
| 17 |
16285075 | Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. | 2005 Oct |
2 |
| 18 |
14764285 | Candesartan reduces cardiovascular death in CHF patients on ACE inhibitor. | 2004 Feb |
1 |
| 19 |
15184734 | ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. | 2004 May-Jun |
1 |
| 20 |
15257162 | Old antihypertensives and new diabetes. | 2004 Aug |
1 |
| 21 |
15384026 | Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. | 2004 Oct |
1 |
| 22 |
15449762 | Angiotensin-receptor blockers in heart failure: evidence from the CHARM trial. | 2004 Aug |
3 |
| 23 |
15492298 | Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. | 2004 Oct 26 |
1 |
| 24 |
15550793 | The use of angiotensin receptor blockers in the treatment of chronic heart failure. | 2004 Dec |
1 |
| 25 |
13678869 | Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. | 2003 Sep 6 |
1 |
| 26 |
13678870 | Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. | 2003 Sep 6 |
2 |
| 27 |
14586718 | Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy. | 2003 Sep |
1 |
| 28 |
11917051 | Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. | 2002 Apr |
1 |
| 29 |
12140730 | AT(1)-receptor blockade and the kidney: importance of non-ACE pathways in health and disease. | 2002 Aug |
1 |
| 30 |
12222554 | Angioedema associated with candesartan. | 2002 Sep |
1 |
| 31 |
12458654 | Switching from ACE inhibitors, beta-blockers, calcium antagonists or diuretics to candesartan improves efficacy and tolerability. | 2002 |
1 |
| 32 |
11260405 | Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus. | 2001 Apr |
1 |
| 33 |
11457745 | Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. | 2001 Jul 17 |
1 |
| 34 |
11881058 | Salt intake and non-ACE pathways for intrarenal angiotensin II generation in man. | 2001 Mar |
1 |
| 35 |
11059629 | Angiotensin II type 1 receptor blockade: a novel therapeutic concept. | 2000 |
1 |
| 36 |
11059637 | Exploring new treatment strategies in heart failure. | 2000 |
1 |
| 37 |
28425795 | Angiotensin II Type 1 Receptor Blockade: a Novel Therapeutic Concept. | 2000 |
1 |
| 38 |
28425812 | Exploring New Treatment Strategies in Heart Failure. | 2000 |
1 |